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Angiotensin II induces fibronectin expression in human peri-
toneal mesothelial cells via ERK1/2 and p38 MAPK.
Background. The renin-angiotensin system has been impli-
cated in the pathogenesis of fibrosis in various organs. However,
its involvement in peritoneal fibrosis, a crucial complication of
peritoneal dialysis, is unclear. Human peritoneal mesothelial
cells (HPMC) play a major role in peritoneal fibrosis by pro-
ducing extracellular matrix (ECM). However, there is scant data
regarding the effect of angiotensin II (Ang II) on ECM expres-
sion and signal transduction pathways in HPMC.
Methods. The concentration of Ang II in the peritoneal dial-
ysis effluent was measured by radioimmunoassay. We investi-
gated the expression of Ang II type 1 (AT1) and type 2 (AT2)
receptors by HPMC. We also examined the effect of Ang II
upon fibronectin production by HPMC, and dissected the re-
ceptor and intracellular signaling pathways involved.
Results. Ang II levels in the peritoneal dialysis effluent at the
onset of peritonitis were 30 times higher than baseline levels.
HPMC expression of AT1 and AT2 receptors was confirmed
at the mRNA and protein level by reverse transcriptase-
polymerase chain reaction (PCR), Western blotting, and im-
munocytochemistry. Quantitative reverse transcriptase-PCR
and Western blotting showed that 10 nmol/L Ang II in-
creased fibronectin mRNA expression followed by secretion
of fibronectin protein. This response was completely inhib-
ited by the AT1 receptor antagonist RNH6270, while the AT2
receptor antagonist PD123319 had no effect. Ang II-induced
fibronectin expression was mediated by the activation of extra-
cellular signal-regulated kinase 1/2 (ERK1/2) and p38 mitogen-
activated protein kinase (p38 MAPK), but not c-Jun N-terminal
kinase.
Conclusion. These results indicate the potential importance
of ERK1/2 and p38 MAPK signaling pathways in Ang II-
induced fibronectin expression in HPMC, and suggest the ther-
apeutic potential of AT1 receptor blockers in the prevention
or treatment of peritoneal fibrosis in patients on peritoneal
dialysis.
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Continuous ambulatory peritoneal dialysis (CAPD)
has been used for more than two decades as a treatment
for end-stage kidney disease. However, peritoneal fibro-
sis is still one of the most important complications, and
eventually causes loss of ultrafiltration and encapsulating
peritoneal sclerosis [1, 2]. There is accumulating evidence
that continuous exposure to bioincompatible dialysis so-
lution components and refractory or repeated episodes
of infectious peritonitis play major roles in the develop-
ment of peritoneal fibrosis [2–4]. Histologically, excessive
deposition of extracellular matrix (ECM) in the subme-
sothelial zone precedes other morphologic changes [5].
Human peritoneal mesothelial cells (HPMC) are capable
of producing ECM, including various collagens (types I,
III, and IV), laminin, and fibronectin [6, 7], and are there-
fore thought to play a major role in the initiation and pro-
gression of peritoneal fibrosis. However, the underlying
biologic mechanisms of peritoneal fibrosis have not been
fully elucidated.
Angiotensin II (Ang II) is a well-recognized and potent
vasoactive peptide, but also exhibits regulatory roles in
inflammation, cell proliferation, apoptosis, and fibrosis
[8–11]. Recent studies indicate that the mitogen-activated
protein kinase (MAPK) cascades are involved in Ang
II-mediated regulation of ECM gene expression via two
distinct receptors, which are the Ang II type 1 (AT1) and
type 2 (AT2) receptors [12].
Ang II concentrations in the effluent of peritoneal
dialysis (PD) have not been reported previously. How-
ever, Delbaere et al [13] reported that the Ang II
concentration in female peritoneal fluid collected during
laparoscopy was higher than in plasma throughout the
menstrual cycle. This indicates the existence of a local
renin-angiotensin system in the peritoneal cavity.
In vivo, there are several studies indicating the re-
lationship between peritoneal fibrosis and the renin-
angiotensin system [14–16]. These studies demonstrate
the efficacy of angiotensin-converting enzyme inhibition
(ACEI) or Ang II receptor blockade (ARB) in pre-
venting the progression of peritoneal fibrosis in animal
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models. However, there is no published data regarding
the expression of Ang II receptors on HPMC, the effect
of Ang II on ECM production by HPMC, or the intracel-
lular signaling pathways involved in Ang II stimulation
of HPMC.
We hypothesized that Ang II induces ECM produc-
tion by HPMC via activation of MAPK. Therefore, in
the present study, we investigated the following issues:
(1) whether HPMC express AT1 and AT2 receptors; (2)
whether Ang II stimulates HPMC to produce fibronectin,
a key ECM component in fibrosis [17]; (3) whether
AT1 and/or AT2 receptor antagonism suppresses Ang
II-induced fibronectin expression by HPMC; (4) whether
activation of extracellular signal-regulated kinase (ERK)
1/2, p38 MAPK, and c-Jun N-terminal kinase (JNK) me-
diates Ang II-induced fibronectin expression.
Our findings demonstrate for the first time that AT1
and AT2 receptors are expressed by HPMC, and that
Ang II increases the mRNA expression and protein se-
cretion of fibronectin via the AT1 receptor. We also show
that Ang II-induced fibronectin expression is mediated
by ERK1/2 and p38 MAPK, but not JNK in HPMC.
METHODS
Reagents
Reagents for these studies were as follows: angiotensin
II, PD123319 (a selective AT2 receptor blocker),
and Protease Inhibitor Cocktail for mammalian tis-
sues (Sigma Chemical Co., St. Louis, MO, USA); fe-
tal calf serum (FCS) (Mitsubishi Kasei Co., Tokyo,
Japan); M199 medium, trypsin-0.01% (wt/vol) ethylene-
diaminetetraacetate solution, penicillin, streptomycin,
L-glutamine, and TRIzol Reagent (Life Technologies
Inc., Grand Island, NY, USA); phosphate-buffered
saline (PBS) (pH 7.2; Nissui Pharmaceutical Co., Tokyo,
Japan); ReverTra Ace (Toyobo, Osaka, Japan); RNase
inhibitor (Promega Co., Madison, WI, USA); Block
Ace (Dainippon Seiyaku Co., Ltd., Tokyo, Japan);
LightCycler Fast Start DNA Master SYBR Green I
(Roche Diagnostics Corp., Idaho Technology, Inc., Idaho
Falls, ID, USA); RNH6270 (a selective AT1 receptor
blocker) was kindly provided by Sankyo Pharmaceuti-
cal Co., Ltd. (Tokyo, Japan); PD98059 (MAPK/ERK ki-
nase 1 inhibitor) and SB203580 (p38 MAPK inhibitor)
(Calbiochem, San Diego, CA, USA); rabbit polyclonal
anti-AT1 receptor and goat polyclonal anti-AT2 recep-
tor (Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA); mouse monoclonal antihuman fibronectin an-
tibody (BD Biosciences, Oxford, UK); antibodies to
phospho-ERK1/2 (Thr202/Tyr204), ERK1/2, phospho-
p38 MAPK (Thr180/Tyr182), p38 MAPK, phospho-JNK
(Thr183/Tyr185), and JNK (Cell Signaling Technology,
Beverly, MA, USA); horseradish peroxidase (HRP)-
conjugated rabbit antigoat IgG antibody and goat
Table 1. Clinical characteristics of the study participants
Normal CAPD
CAPD patients with
patients peritonitis
N = 5 N = 5 P valuea
Age years 51.9 ± 2.4 54.4 ± 7.7 NS
Gender (male/female) 3/2 3/2 NS
Primary disease CGN:4 CGN:3
DN:1 DN:2 NS
Duration of CAPD years 5.9 ± 3.1 3.7 ± 0.8 NS
Ang II concentration pmol/L 11.1 ± 2.7 336.8 ± 81.7 <0.001
Abbreviations are: CAPD, continuous ambulatory peritoneal dialysis; CGN,
chronic glomerulonephritis; Ang II, angiotensin II; DN, diabetic nephropathy;
NS, not significant.
a Mann-Whitney U test.
antimouse IgG antibody (Dako Cytomation, Carpin-
teria, CA, USA); fluorescein isothiocyanate (FITC)-
conjugated goat antirabbit IgG antibody, rabbit antigoat
IgG antibody and 4,6-diamidino-2-phenylindole (DAPI)
(Molecular Probes, Leiden, The Netherlands); HRP-
conjugated donkey antirabbit IgG, PVDF membranes,
and the enhanced chemiluminescence (ECL) West-
ern blotting detection system (Amersham Pharmacia
Biotech, Buckinghamshire, UK); BCA protein assay
reagents (Pierce, Rockford, IL, USA).
Radioimmunoassay
To measure the Ang II concentration in the PD ef-
fluent, we enrolled 10 patients on CAPD at Hiroshima
University Hospital (Hiroshima, Japan). The PD effluent
following an overnight dwell was collected from five pa-
tients during normal uncomplicated dialysis and another
five patients at the onset of infectious peritonitis. The ef-
fluent was centrifuged at 1000g for 10 minutes at 4◦C, and
supernatants aliquoted and stored at −80◦C. The con-
centration of Ang II in the PD effluent was measured by
a radioimmunoassay kit (Mitsubishi Kagaku BCL, Inc.,
Tokyo, Japan) according to the manufacturer’s instruc-
tions. The clinical characteristics of the study participants
are shown in Table 1. All the patients participating in this
study gave full informed consent.
Cell cultures
HPMC were isolated from human omentum as de-
scribed previously [6]. Chemicals and tissue culture plas-
tics were as described in our earlier studies [18]. HPMC
were identified by their morphologic characteristics as
visualized by inverted phase-contrast microscopy and by
the presence of vimentin and cytokeratin, and by the ab-
sence of human factor VIII, by immunofluorescence mi-
croscopy. Harvesting of the omentum was permitted by
the Medical Ethics Committee of Hiroshima Graduate
School of Biomedical Sciences, and informed consent was
obtained from each patient. All data presented are from
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experiments performed with confluent HPMC from the
second to third passage. All cells were washed and growth
arrested for 48 hours in control standard M199 medium
containing 0.1% FCS (vol/vol) prior to Ang II stimula-
tion. Human umbilical vein endothelial cells (HUVEC)
were obtained from the American Tissue Type Culture
Collection (Manassas, VA, USA).
Reverse transcriptase-PCR
HPMC were cultured in 60-mm dishes (both at 1 ×
106 cells/dish). Quiescent cells were washed twice with
PBS, and total RNA was extracted according to the
method of Chomczynski and Sacchi [19] with TRI-
zol reagent. Oligo dT-primed reverse transcription was
performed at 30◦C for 10 minutes, and 42◦C for 30 min-
utes after denaturation of the RNA at 95◦C for 10 min-
utes with reverse transcriptase (ReverTra Ace; Toyobo)
and RNase inhibitor. The primer set used to detect the
AT1 and AT2 receptors were as follows: AT1 (388-bp);
sense 5′- CTGAATAACTCACTGATGCC-3′, antisense
5′- TAGGTAATTGCCAAAGGGCC -3′, AT2 (191-bp);
sense 5′-TTCCCTTCCATGTTCTGACC-3′, antisense
5′-AAACACACTGCGGAGCTTCT-3′. PCR for AT1
receptor was performed with denaturation for 1 minute
at 95◦C, annealing for 1 minute at 52◦C, and extension at
72◦C for 2 minutes. After 40 cycles, the final product was
extended for 3 minutes at 72◦C. PCR for AT2 receptor
was performed with denaturation for 1 minute at 95◦C,
annealing for 1 minute at 59◦C, and extension at 72◦C for
2 minutes. After 32 cycles, the final product was extended
for 3 minutes at 72◦C. A Program Temp Control System
PC-800 (Astec; Fukuoka, Japan) was used. PCR products
were separated by 1.5% agarose gel electrophoresis and
visualized by ethidium bromide staining. Non–reverse-
transcribed RNA was used as a template for the negative
control. HUVEC were used as a positive control [20].
Immunocytochemistry
Quiescent HPMC were cultured on 8-well chamber
slides (Nunc, Naperville, IL, USA) and fixed in 4%
paraformaldehyde for 20 minutes at room temperature.
After washing three times with PBS containing 0.1%
TritonX-100, (PBST) cells were blocked for one hour
in PBS containing 20% Block Ace, and then incubated
overnight at 4◦C with the primary antibody. A rabbit poly-
clonal antihuman AT1 receptor antibody and a goat poly-
clonal antihuman AT2 antibody were used at dilutions
of 1:400 and 1:100 in PBS, respectively. After incubation
with the primary antibody, cells were washed five times
with PBST, and incubated with FITC-conjugated goat an-
tirabbit IgG (5 lg/mL) for one hour at room tempera-
ture. Nuclei were counterstained with 300 nmol/L DAPI
for three minutes, and stained specimens were examined
under a laser scanning microscope (AX-80, Olympus,
Tokyo, Japan).
Quantitative RT-PCR
HPMC (2 × 105 cells/well) were seeded on 6-well
plates, and grown until 80% confluent. Quiescent cells
were then incubated with various concentrations of Ang
II for the specified time. Total RNA was extracted
using the TRIzol reagent and equal amounts (2 lg)
of total RNA from each sample were converted to
cDNA by M-MLV reverse transcriptase RNaseH- with
oligo dT20 primer in a 20-lL reaction volume. We
performed real-time PCR using the LightCycler quick
system 350S (Roche Diagnostics, Tokyo, Japan). The
RT reaction was subjected to PCR amplification using
LightCycler Fast Start DNA Master SYBR Green I in a
20-lL reaction volume with 0.3 lmol/L of each primer
and 3 mmol/L MgCl2. b-actin was used as the inter-
nal control. The primer sequences were as follows: fi-
bronectin (421-bp), sense 5′-GCCTGGTACAGAATA
TGTAGTG-3′ and antisense 5′-ATCCCAGCTGATC
AGTAGGCTGGTG-3′; b-actin (260-bp), sense 5′-
GCAAAGACCTGTACGCCAAC-3′ and antisense 5′-
CTAGAAGCATTTGCGGTGGA-3′. The amplification
program was 95◦C for 10 minutes, and then 40 cycles con-
sisting of 95◦C for 10 seconds, 62◦C for 10 seconds, and
72◦C for 10 seconds. Amplification products were ana-
lyzed by a melting curve, which confirmed the presence
of a single PCR product in all reactions apart from the
negative controls. Quantification of PCR products was
measured by a fit-point analysis, and melting curve anal-
ysis was performed in all measurements. The results of
fibronectin were normalized by b-actin.
Western blotting
HPMC and HUVEC were seeded into 75-cm2 tissue
culture flasks, and cultured until 80% confluent. Qui-
escent cells were washed twice with ice-cold PBS, and
then lysed in 500 lL of ice-cold lysis buffer (10 mmol/L
Tris-HCl pH 7.4, 100 mmol/L NaCl, 1 mmol/L EDTA,
1 mmol/L EGTA, 1 mmol/L NaF, 2 mmol/L Na3VO4,
1% Triton X-100, 10% glycerol, 0.5% deoxycholate,
1 mmol/L PMSF, 10% Protease Inhibitor Cocktail for
mammalian tissues; Sigma). The lysates were put on ice
and vortexed every 2 minutes for 10 minutes. Lysates were
then centrifuged at 15,000g for 20 minutes at 4◦C, and
supernatants aliquoted and stored at −80◦C. The protein
content of cell lysates was determined by the BCA protein
assay. Lysates (15 lg of protein) were separated on 10%
polyacrylamide gels using SDS-PAGE, and transferred to
PVDF membranes. The blots were blocked overnight at
4◦C with 20 mmol/L Tris-HCl pH 7.4, 140 mmol/L NaCl
with 0.05% Tween 20 (TBST buffer) containing 5% non-
fat dried milk, and then incubated for 2 hours at 4◦C with
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Cell type HUVEC HPMC
B
50 kD
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Cell type HUVEC HPMC
50 kD
AT 1 receptor mRNA
Cell type HUVEC HPMC
RT (+) (−) (+) (−)
A
388 bp
AT 2 receptor mRNA
Cell type HUVEC HPMC
RT (+) (−) (+) (−)
191 bp
C
Fig. 1. Human peritoneal mesothelial cells
(HPMC) express angiotensin II (Ang II) type
1 and 2 receptors. (A) RT-PCR was used to
detect mRNA for the Ang II type 1 (A-I) and
type 2 (A-II) receptors in quiescent HPMC.
The predicted length of each PCR product
(388-bp and 191-bp, respectively) is shown
by an arrow. The negative control was non–
reverse-transcribed RNA, while human um-
bilical vein endothelial cells (HUVEC) served
as positive control. (B) Western blotting of
quiescent HPMC or HUVEC was used to de-
tect the presence of Ang II type 1 (B-I) and
type 2 (B-II) receptors. Data shown are rep-
resentative of similar results obtained from 3
separate experiments. (C) Immunocytochem-
istry was used to detect the Ang II type 1
(C-I) and type 2 (C-II) receptors in quies-
cent HPMC, with nuclei counterstained with
DAPI. These photomicrographs are represen-
tative of similar results obtained from 3 sep-
arate experiments. Magnification ×400. For
negative control, 5% bovine serum albumin
was used instead of the primary antibody (C-
III). The specificity of the Western blotting
and immunocytochemistry results was con-
firmed by incubation of the primary antibod-
ies with their respective blocking peptides
(data not shown).
each primary antibody (1:200 dilution). After washing
three times in TBST buffer, blots were incubated with
secondary antibody (HRP-conjugated donkey antirabbit
IgG at a 1:5000 dilution) for two hours at room tempera-
ture, and the reaction products were detected by the ECL
Western blotting detection system. HUVEC were used as
a positive control [20].
For detection of phospho-ERK1/2 (Thr202/Tyr204),
ERK1/2, phospho-p38 MAPK (Thr180/Tyr182), p38
MAPK, phospho-JNK (Thr183/Tyr185), and JNK,
HPMC were seeded into 25-cm2 tissue culture flasks and
grown to 80% confluence. Quiescent cells were incubated
with Ang II for the specified time, and then lysed with
100 lL of ice-cold lysis buffer and stored as described
above. Lysates (20 lg of protein) were separated on 10%
polyacrylamide gels using SDS-PAGE, and transferred
to PVDF membranes.
For detection of supernatant fibronectin, HPMC were
seeded into 25-cm2 tissue culture flasks and grown to 80%
confluence. Quiescent cells were incubated with Ang II
for the specified time. The supernatants were then col-
lected and centrifuged at 1000g for 10 minutes at 4◦C.
Supernatants (15 lg of protein, determined by the BCA
protein assay) were separated on 8% polyacrylamide gels
using SDS-PAGE, and transferred to PVDF membranes.
The blots were blocked for two hours at room temper-
ature with TBST containing 5% nonfat dried milk, and
then incubated overnight at 4◦C with each primary anti-
body (1:1000 dilution for MAPK, 1:5000 dilution for fi-
bronectin). After washing three times in TBST buffer,
blots were incubated with HRP-conjugated secondary
antibody (1:5000 dilution) for one hour, and the reaction
products were detected by the ECL Western blotting de-
tection system using x-ray film. The intensity of each band
was determined using NIH image software (version 1.6).
Statistical analysis
Results are expressed as mean ± SEM of at least
three individual experiments. Statistical analysis was per-
formed with analysis of variance (ANOVA) followed by
Tukey’s post-hoc test unless otherwise stated. Differences
were deemed significant at P < 0.05.
RESULTS
Ang II concentrations are elevated in the effluent
of patients with infectious peritonitis
The Ang II concentration in the PD effluent was sig-
nificantly higher at the onset of infectious peritonitis
than during basal conditions (336.8 ± 81.7 vs. 11.1 ±
2.7 pmol/L, respectively) (Table 1).
Human peritoneal mesothelial cells express Ang II type
1 and 2 receptors
RT-PCR and Western blotting identified the presence
of both AT1 and AT2 receptors in quiescent HPMC
(Fig. 1A and B). As a positive control, HUVEC were
shown to express both AT1 and AT2 receptors. Immuno-
cytochemistry also demonstrated the expression of both
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Fig. 2. Angiotensin II (Ang II) induces fibronectin gene expression in
human peritoneal mesothelial cells (HPMC). (A) HPMC were incu-
bated in the absence or presence of 10 nmol/L Ang II for the indicated
times, and real time-RT-PCR was performed. Graph shows the relative
mRNA levels of fibronectin normalized to b-actin in the absence (open
bars) or presence (filled bars) of 10 nmol/L Ang II for the indicated
times relative to 0-hour control levels. (B) HPMC were incubated for
6 hours in the presence of various concentrations of Ang II, and real
time-RT-PCR was performed. Graph shows the relative mRNA levels
in various concentrations of Ang II normalized to b-actin relative to
control levels. Values are mean ± SEM of 9 individual experiments.
∗P < 0.05.
the AT1 and AT2 receptors (Fig. 1C). The specificity of
the Western blotting and immunocytochemistry results
was confirmed by incubation of the primary antibodies
with their respective blocking peptides (data not shown).
Ang II induces fibronectin gene and protein expression
in human peritoneal mesothelial cells
The addition of 10 nmol/L Ang II induced a signifi-
cant increase in fibronectin mRNA expression (1.70-fold)
within six hours that was maintained for the 24-hour study
period (Fig. 2A). The effect of different doses of Ang II on
fibronectin mRNA expression was investigated at the six-
hour time point. Incubation with 1 nmol/L Ang II induced
a significant increase (1.35-fold) in fibronectin mRNA
levels, with greater increases in fibronectin mRNA evi-
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Fig. 3. Angiotensin II (Ang II) induces fibronectin protein expression
in human peritoneal mesothelial cells (HPMC). (A) HPMC were incu-
bated in the absence or presence of 10 nmol/L Ang II for the indicated
times, and Western blotting was performed. Graph shows the levels of
fibronectin protein in the culture supernatant (25 lL per lane) in the
absence (open bars) or presence (filled bars) of 10 nmol/L Ang II for
the indicated times relative to 24-hour control levels. (B) HPMC were
incubated for 24 hours in the presence of various concentrations of Ang
II, and Western blotting was performed. Graph shows the relative levels
of fibronectin protein in the culture supernatant (15 lg loaded per lane)
in various concentrations of Ang II relative to control levels. Values are
mean ± SEM of 3 individual experiments. ∗P < 0.05 vs. control.
dent with 10 and 100 nmol/L Ang II (1.70- and 1.46-fold)
(Fig. 2B).
Stimulation of HPMC with 10 nmol/L Ang II also
caused a significant time-dependent increase in the secre-
tion of fibronectin protein into the culture medium. This
was evident following Ang II stimulation for 24 hours
(Fig. 3A).
The quantification of secreted fibronectin protein in-
duced by different concentrations of Ang II was per-
formed by Western blotting at the 24-hour time point
(Fig. 3B). Incubation with 10 nmol/L Ang II signifi-
cantly increased the secretion of fibronectin (1.83-fold).
Fibronectin protein was undetectable in control media
that had not been exposed to HPMC.
These results demonstrate that Ang II up-regulates
fibronectin mRNA and protein expression in cultured
HPMC.
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Fig. 4. Angiotensin II (Ang II) induces fibronectin expression in hu-
man peritoneal mesothelial cells (HPMC) via the angiotensin II type 1
(AT1) receptor. Quiescent HPMC were incubated with various concen-
trations of RNH6270 (active form of olmesartan; selective AT1 recep-
tor blocker) or vehicle control for 30 minutes before stimulation with
10 nmol/L Ang II. (A) Real time-RT-PCR was performed to assess
the levels of fibronectin mRNA expression. Graph shows the relative
fibronectin mRNA levels normalized to b-actin relative to control. Val-
ues are mean ± SEM of 5 individual experiments. ∗P < 0.05, †P < 0.05
vs. control. (B) Graph shows the levels of fibronectin protein in the
culture supernatant (15 lg loaded per lane) relative to control levels.
Values are mean ± SEM of 3 individual experiments. ∗P < 0.05.
Ang II induces fibronectin expression
via the AT1 receptor
Since HPMC express both the AT1 and AT2 recep-
tors, we examined which receptor was involved in Ang
II-induced fibronectin expression. Incubation of HPMC
with the AT1 receptor antagonist RNH6270 abolished the
up-regulation of fibronectin mRNA level by 10 nmol/L
Ang II in a dose-dependent manner (Fig. 4A). Accord-
ingly, up-regulation of fibronectin protein expression was
completely inhibited by RNH6270 at 1 lmol/L (Fig. 4B).
In contrast, the AT2 receptor antagonist PD123319 had
no effect upon Ang II-induced fibronectin mRNA levels
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Fig. 5. Angiotensin II type 2 (AT2) receptor blocker does not af-
fect angiotensin II (Ang II)-induced fibronectin expression in human
peritoneal mesothelial cells (HPMC). Quiescent HPMC were incu-
bated with various concentrations of PD123319 (selective AT2 receptor
blocker) or vehicle control for 30 minutes before stimulation with 10
nmol/L Ang II. (A) Real time-RT-PCR was performed to assess the
levels of fibronectin mRNA expression. Graph shows the relative fi-
bronectin mRNA levels normalized to b-actin relative to control. Val-
ues are mean ± SEM of 5 individual experiments. ∗P < 0.05 vs. control.
(B) Graph shows the levels of fibronectin protein in the culture su-
pernatant (15 lg of protein loaded per lane) relative to control levels.
Values are mean ± SEM of 3 individual experiments. ∗P < 0.05.
and fibronectin protein expression at 10 lmol/L (Fig. 5A
and B). Both RNH6270 and PD123319 had no effect on
the expression of fibronectin in the absence of Ang II
stimulation (data not shown). These results indicate that
Ang II induces fibronectin expression via the AT1 recep-
tor in HPMC.
Ang II induces activation of ERK1/2 and p38 MAPK, but
not JNK in HPMC
Having demonstrated that Ang II induces fibronectin
expression via the AT1 receptor, we examined the intra-
cellular signaling mechanisms in HPMC. Ang II is known
1132 Kiribayashi et al: Angiotensin II induces fibronectin expression via ERK1/2 and p38 MAPK
Phospho-ERK 1/2
Total ERK 1/2
0
1.0
2.0
3.0
Ph
os
ph
o/
to
ta
l E
RK
 1
/2
, fo
ld
0 2 5 10 30 60 min
*P < 0.05 vs. time 0
*
B
A
Phospho-p38 MAPK
Total p38 MAPK
0
1.0
2.0
Ph
os
ph
o/
to
ta
l p
38
 M
AP
K,
 fo
ld
0 2 5 10 30 60 min
*P < 0.05 vs. time 0
*
*
*
D
C
Phospho-p54 JNK
Phospho-p46 JNK
Total p54 JNK
Total p46 JNK
0
1.0
Ph
os
ph
o/
to
ta
l J
NK
, fo
ld
0 2 5 10 30 60 min
F
E
NS
Fig. 6. Angiotensin II (Ang II) activates ERK1/2 and p38 MAPK, but
not JNK in human peritoneal mesothelial cells (HPMC). Quiescent
HPMC were stimulated with 10 nmol/L Ang II for the times indicated,
and then cells were lysed and analyzed by Western blotting for (A)
phosphorylated and total ERK1/2, (C) phosphorylated and total p38
MAPK, and (E) phosphorylated and total JNK. (B) Ratio of phospho-
ERK1/2 to total ERK1/2. (D) Ratio of phospho-p38 MAPK to total p38
to induce a number of cellular responses via ERK1/2, p38
MAPK, and JNK in various cell types [21–23]. There-
fore, we examined whether Ang II treatment activates
these kinases in HPMC. As shown in Figure 6, stimu-
lation of HPMC with 10 nmol/L Ang II induced a rapid
activation (phosphorylation) of ERK1/2 and p38 MAPK,
which peaked within several minutes and then gradually
decreased (2.7-fold at 5 minutes and 2.0-fold at 2 minutes
vs. control, respectively), whereas JNK was not activated.
Blots for total MAPKs remained constant throughout the
duration of the experiments.
Ang II induces fibronectin expression via ERK1/2 and
p38 MAPK
Addition of 0.1 to 10 lmol/L PD98059, a specific
MAPK/ERK kinase 1 inhibitor, substantially inhibited
ERK1/2 phosphorylation in Ang II-stimulated HPMC
(Fig. 7A and B). Accordingly, addition of 10 lmol/L
PD98059 completely inhibited fibronectin secretion into
the media (Fig. 7C and D).
Addition of 0.2 to 20 lmol/L SB203580, a specific in-
hibitor of p38 MAPK, significantly reduced the phospho-
rylation of p38 MAPK (Fig. 8A and B). Western blotting
showed that 20 lmol/L SB203580 completely inhibited
Ang II-induced fibronectin secretion (Fig. 8C and D).
These data indicate that ERK1/2 and p38 MAPK play
a major role in Ang II-induced fibronectin expression,
whereas JNK is not involved.
DISCUSSION
Peritoneal fibrosis is a crucial complication in CAPD
patients, and is due to various factors, including the
bioincompatibility of dialysate (high glucose content, low
pH, hyperosmolality, lactate, glucose degradation prod-
ucts, etc.) and severe or repeated episodes of infectious
peritonitis [2–4]. Recently, various improvements have
been made to the constituents of CAPD fluid (icodex-
trin, neutralized pH, sodium bicarbonate, etc.), as well as
peritoneal dialysis devices (twin-bag system, connecting
devices with ultraviolet light, etc.). These modifications
have improved clinical outcome, but have not prevented
peritoneal fibrosis, thereby suggesting the existence of
unknown mechanisms involved in the initiation and pro-
gression of peritoneal fibrosis.
In vitro and in vivo studies have demonstrated that
the renin-angiotensin system plays an important role in
fibrosis affecting various organs, such as kidney [24] and
heart [25]. However, in contrast with the well-recognized
MAPK. (F) Ratio of phospho-p46 and p54 JNK to total p46 and p54
JNK. Western blots shown are representative of similar results obtained
from 3 separate experiments. Values are mean ± SEM of 3 individual
experiments. ∗P < 0.05 vs. time 0.
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Fig. 7. Angiotensin II (Ang II)-induced fibronectin expression in
human peritoneal mesothelial cells (HPMC) operates via ERK1/2.
(A) Quiescent HPMC were incubated with various concentrations of
PD98059 or 0.02% DMSO vehicle control for 60 minutes before incu-
bation with 10 nmol/L Ang II or control media. HPMC were stimulated
with 10 nmol/L Ang II for 5 minutes, and then cells were lysed and ex-
amined for phosphorylation of ERK1/2 by Western blotting. The blots
shown are representative of similar results obtained from 4 separate ex-
periments. Preincubation with 10 lmol/L PD98059 substantially inhib-
ited both basal and Ang II-induced ERK1/2 activation compared with
0.02%DMSO vehicle control. (B) Graph shows the ratio of phospho- to
total ERK1/2. Values are mean±SEM of 3 individual experiments. ∗P <
0.05. (C) Quiescent HPMC were incubated with 10 lmol/L PD98059
or 0.02% DMSO vehicle control for 60 minutes before incubation with
10 nmol/L Ang II or control media. The representative blots show se-
creted fibronectin protein. (D) Graph shows the levels of fibronectin
protein in the culture supernatant (15 lg of protein loaded per lane)
relative to control levels. Values are mean ± SEM of 3 individual ex-
periments. ∗P < 0.05.
efficacy of ACEI or ARB in the treatment of renal or
cardiovascular diseases [24], very limited information is
available regarding the relationship between the renin-
angiotensin system and the pathogenesis of peritoneal
fibrosis.
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Fig. 8. Angiotensin II (Ang II)-induced fibronectin expression in hu-
man peritoneal mesothelial cells (HPMC) operates via p38 MAPK.
(A) Quiescent HPMC were incubated with various concentrations of
SB203580 or 0.02% DMSO vehicle control for 60 minutes before incu-
bation with 10 nmol/L Ang II or control media. HPMC were stimulated
with 10 nmol/L Ang II for 2 minutes, and then cells were lysed and ex-
amined for phosphorylation of p38 MAPK by Western blotting. The
blots shown are representative of similar results obtained from 4 sepa-
rate experiments. Preincubation with 20 lmol/L SB203580 substantially
inhibited both basal and Ang II-induced p38 MAPK activation com-
pared with 0.02% DMSO vehicle control. (B) Graph shows the ratio
of phospho- to total p38 MAPK. Values are mean ± SEM of 4 individ-
ual experiments. ∗P < 0.05. (C) Quiescent HPMC were incubated with
20 lmol/L SB203580 or 0.02% DMSO vehicle control for 60 minutes
before incubation with 10 nmol/L Ang II or control media. The repre-
sentative blots show secreted fibronectin protein. (D) Graph shows the
levels of fibronectin protein in the culture supernatant (15 lg of protein
loaded per lane) relative to control levels. Values are mean ± SEM of
3 individual experiments. ∗P < 0.05.
The expression of AT1 and AT2 receptors has been
investigated in mesangial cells [23], macrophages [26],
HUVEC [20], but their presence on HPMC had not re-
ceived attention. The present study demonstrates for the
first time that HPMC express both AT1 and AT2 recep-
tors, and that Ang II increases the mRNA expression and
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protein secretion of fibronectin via activation of ERK1/2
and p38 MAPK, but not JNK. In addition, we demon-
strate that these responses are specifically mediated by
the AT1 receptor because RNH6270, a specific inhibitor
of AT1 receptor, suppressed Ang II-induced expression
of fibronectin in HPMC, while the AT2 receptor blocker
PD123319 had no effect. These findings in HPMC are con-
sistent with a previous study in cultured mesangial cells
in which Ang II induced transcription and biosynthesis
of fibronectin via the AT1 receptor [27].
Ang II stimulation of quiescent HPMC resulted in in-
creased expression of fibronectin mRNA followed by in-
creased secretion of fibronectin protein into the culture
media. Although maximal induction of Ang II-induced
fibronectin secretion was seen with 10 nmol/L Ang II, an
increase in fibronectin mRNA was observed with Ang II
concentrations ranging between 1 to 100 nmol/L. These
levels are high compared with those found in plasma, but
local Ang II levels in the peritoneal cavity may be signifi-
cantly higher than those found in the circulation, as we de-
scribed above. The elevated levels of Ang II in the effluent
of infectious peritonitis might result from local induction
by activated neutrophils, which are capable of generating
Ang II with cathepsin G [28, 29]. Thus, considering di-
lution by dialysate, it is conceivable that concentrations
of Ang II including 1 to 100 nmol/L may be present lo-
cally in the peritoneal cavity and, therefore, have the po-
tential to influence the behavior of HPMC. This may be
one of the mechanisms whereby Ang II regulates tissue
repair and remodeling following peritoneal injury espe-
cially after infectious peritonitis. However, prolonged or
excessive activation of the renin-angiotensin system in
the peritoneal cavity during the pathophysiologic condi-
tions associated with CAPD may initiate or exacerbate
peritoneal fibrosis.
The ability of Ang II to up-regulate fibronectin ex-
pression by HPMC raised the question of the signaling
pathways involved. ERK1/2, p38 MAPK, and JNK are
cascades of serine/threonine kinases that transduce sig-
nals from the cell surface to the nucleus in response to
growth factors and cellular stress [30, 31]. These kinases
are reported to mediate various cell responses of HPMC.
For example, D-glucose-induced prostaglandin E2 syn-
thesis is via activation of ERK1/2 [32], while fibronectin
mRNA expression is via p38 MAPK [33]. Furthermore,
both the ERK1/2 and p38 MAPK pathways are inde-
pendently required for TGF-b-induced up-regulation of
gene expression for plasminogen activator inhibitor type-
1 [34]. However, there have been no reports regarding the
role of MAPK signaling pathways activated by Ang II in
HPMC. The present study shows that Ang II-induced fi-
bronectin expression in HPMC was dependent on signal-
ing through ERK1/2 and p38 MAPK, but not JNK. This
finding is consistent with a similar study in renal intersti-
tial fibroblasts [35].
Many of the stimulants that activate the ERK1/2 path-
way also activate the p38 MAPK pathway without acti-
vating the JNK pathway [36–38]. Indeed, the ERK1/2
and p38 MAPK pathways share common elements in
both their upstream signaling cascades [38, 39] and down-
stream substrates [40, 41]. The requirement of ERK1/2
and p38 MAPK signaling for Ang II-induced fibronectin
expression in HPMC indicates, at least in part, that ac-
tivation of both kinases may play an important role
in accumulation of fibronectin in the peritoneum. Fur-
ther studies are required to clarify whether activation of
ERK1/2 and p38 MAPK contributes solely to transcrip-
tional regulation of the fibronectin gene, or if they have
an additional role in post-transcriptional events involved
in fibronectin expression.
CONCLUSION
This study demonstrates that Ang II stimulation of
HPMC increased mRNA expression and secretion of fi-
bronectin protein. Ang II-induced fibronectin expression
is via the AT1 receptor and signaling through the ERK1/2
and p38 MAPK pathways. These results suggest the po-
tential importance of these MAPK pathways in Ang II-
induced initiation and progression of peritoneal fibrosis
and the therapeutic potential of ARB in the prevention
or treatment of peritoneal fibrosis in patients receiving
CAPD.
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